Core Viewpoint - Relmada Therapeutics, Inc. is actively participating in the Leerink Partners Global Healthcare Conference, highlighting its commitment to advancing innovative therapies in oncology and central nervous system disorders [1]. Group 1: Conference Participation - The CEO Sergio Traversa and CFO Maged Shenouda will represent the company at the conference held in Miami, Florida from March 8-11, 2026 [1]. - A fireside chat is scheduled for March 10, 2026, at 8:40 AM ET, with a webcast available for interested parties [2]. - Management will also be available for one-on-one investor meetings during the conference, indicating an opportunity for direct engagement with investors [2]. Group 2: Company Overview - Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions [4]. - The company's lead candidates, NDV-01 and sepranolone, are progressing through mid-stage clinical development, aiming to address significant unmet medical needs [4].